𝐀𝐠𝐞: 70 years old 𝐏𝐒𝐀 𝐥𝐞𝐯𝐞𝐥: 15 ng/ml, rising kinetic 𝐃𝐑𝐄: Adenoma grade III mpRMI 2 years before PI-RADS 4 in left-lateralized base, biopsy (-) "𝘛𝘩𝘦 𝘴𝘢𝘮𝘦 𝘢𝘨𝘨𝘳𝘦𝘴𝘴𝘪𝘷𝘦 𝘭𝘦𝘴𝘪𝘰𝘯 𝘵𝘩𝘢𝘵 𝘸𝘦 𝘴𝘢𝘸 (𝘢𝘯𝘥 𝘮𝘢𝘵𝘤𝘩𝘦𝘥 𝘸𝘪𝘵𝘩 𝘘𝘗-𝘗𝘳𝘰𝘴𝘵𝘢𝘵𝘦) 𝘸𝘢𝘴 𝘵𝘩𝘦 𝘰𝘯𝘦 𝘵𝘩𝘢𝘵 𝘴𝘩𝘰𝘸𝘦𝘥 𝘵𝘩𝘦 𝘮𝘰𝘴𝘵 𝘶𝘱𝘵𝘢𝘬𝘦, 𝘢𝘯𝘥 𝘪𝘵 𝘸𝘢𝘴 𝘢𝘭𝘴𝘰 𝘢 𝘭𝘰𝘤𝘢𝘭𝘪𝘻𝘦𝘥 𝘵𝘶𝘮𝘰𝘳 𝘵𝘩𝘢𝘵 𝘰𝘯𝘭𝘺 𝘩𝘢𝘥 𝘵𝘩𝘦 𝘱𝘳𝘰𝘴𝘵𝘢𝘵𝘦 𝘭𝘦𝘴𝘪𝘰𝘯 𝘢𝘯𝘥 𝘯𝘰𝘵𝘩𝘪𝘯𝘨 𝘦𝘭𝘴𝘦 𝘪𝘯 𝘵𝘩𝘦 𝘰𝘷𝘦𝘳𝘢𝘭𝘭 𝘴𝘵𝘢𝘨𝘪𝘯𝘨 𝘰𝘧 𝘵𝘩𝘦 𝘱𝘢𝘵𝘪𝘦𝘯𝘵" - Dr. Margarita García Fontes. ▶ Watch the full webinar here: https://bit.ly/3wSrNfo
Lung cancer remains one of the most challenging cancers, and early detection is crucial for effective treatment. 🤍 As a contribution to #WorldLungCancerDay, and because each study brings us one step closer to better #patientcare, we wanted to share our latest research, led by Almudena Fuster Matanzo and Alfonso Picó. 📋 This comprehensive meta-analysis explores the potential of artificial intelligence in classifying tumor genetic profiles through CT scans. Our review encompasses 89 models, analyzing data from 32,084 non-small cell lung cancer (NSCLC) patients. The findings demonstrate promising correlations between imaging and genetic features. 🔗 Read the full study: https://lnkd.in/ei66kFNe #LungCancer #CancerResearch
Lots of exciting news and inspiring conversations have happened in July: 🇦🇺 QP-Prostate is now approved, available, and ready for use in Australia. 🏥 The Servicio de Radiología Hospital Universitario Ramón y Cajal has recently adopted QP-Prostate to enhance diagnostic protocols for #prostatecancer. 📋 A new case study on “Predicting survival, neurotoxicity, and response in B-Cell lymphoma patients treated with CAR-T therapy using an imaging features-based model” is now available on our website. Stay updated on the latest advancements in #patientcare, #medicalimaging, and #radiology in this newest edition of our monthly newsletter:
QP-Prostate is the leading AI solution to improve prostate cancer detection. Need proof? Book a demo! https://lnkd.in/d-MVjMiV
🇦🇺 QP-Prostate® CAD has been officially approved for use in Australia! We are really proud to announce that, as of today, Quibim's #QPProstate technology can be used by Australian physicians for #AI-driven lesion detection thanks to algorithms trained with post-biopsy pathology data as ground truth. To find out more, contact us! https://lnkd.in/d-MVjMiV
According to the National Cancer Institute (NCI) in the United States, an estimated 71,100 people will be diagnosed with some form of head and neck cancer in 2024 in the US. Unfortunately, about 16,110 people will die from these diseases. #EarlyDetection is crucial in the fight against these cancers, and #AI is playing an increasingly vital role in this endeavor. 📋 In this context, on the World Head and Neck Cancer Day, we highlight a captivating conversation with Dr. Gema Bruixola, head and neck #oncologist. Read more about this insightful conversation: https://bit.ly/3wZgDp4 #WorldHeadandNeckCancerDay #AIinHealthcare #MedicalImaging #CancerResearch
With millions of new cases diagnosed annually, #ProstateCancer continues to be a significant global health challenge. The #FLUTEproject is changing the game by refining predictions of aggressive prostate cancer, aiming to reduce unnecessary biopsies and alleviate the physical and emotional burden on patients. By integrating QP-Prostate®, the FLUTE Project - AI & Prostate Cancer enhances the accuracy of prostate cancer diagnostics. Early data shows promising results, with a marked decrease in invasive procedures and with more precise, targeted treatments. Read here more ⬇ about the impact of this project on prostate cancer treatment.
🧠 Incredible advances have guided a new era of brain research, in which technology could radically transform our ability to image human brain tissue. Three-dimensional microscopy, tissue expansion and advanced computational techniques are enabling researchers to explore the complexities of the brain at the macroscopic and microscopic levels with unprecedented accuracy and speed. The impact of this sophisticated imaging system is significant, extending beyond academic research to critical clinical applications. Collaboration between academic progress and specialized imaging products such as QP-Brain could be transformative for researchers and #healthcare professionals seeking precision in neuroimaging. On #WorldBrainDay, we celebrate what connections between innovative research and clinical practice are achieving to advance the boundaries of what's possible in medical science and #patientcare. #BrainResearch #HealthTechnology
🗣️ In his talk at hashtag#ECR2024, David Bazaga, Product Lead at Quibim, highlighted critical challenges and innovative solutions in #ProstateCancer diagnosis. Here's a glimpse of David's presentation: "PSA testing has suboptimal sensitivity and specificity, often leading to unnecessary referrals for MRI and missed cancer diagnoses. Our QP-Prostate solution is designed to address these bottlenecks by providing fully automated lesion detection for clinically significant prostate cancer, improving diagnostic accuracy and efficiency." Are you curious to learn more about how QP-Prostate is transforming prostate cancer diagnosis? 📲 Watch the full video presentation here: https://bit.ly/3Wr21ZB #AIinHealthcare #MedicalImaging #Radiology #Innovation #QPProstate
Want to know more about Quibim? Subscribe to our 𝗟𝗶𝗻𝗸𝗲𝗱𝗜𝗻 𝗻𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿 and get ready to learn about our company's impact on the world of precision medicine from the inside! #medicine #precisionmedicine #radiology
